Literature DB >> 8144133

Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis.

G Enblad1, C Sundstrom, B Glimelius.   

Abstract

The number of infiltrating eosinophils were counted in tumour specimens from an unselected material of 140 cases of primary Hodgkin's disease (HD) and divided in three groups. Twenty-six cases (19 per cent) showed heavy infiltration (> 200 eosinophils/10 vision fields (VF)), 51 (36 per cent) moderate infiltration (11-200 eosinophils/10 VF and 63 virtually no infiltration (< 10 eosinophils/10 VF). The eosinophilic infiltration was significantly more pronounced in the nodular sclerosis subtype. Cases with heavy infiltration had a significantly worse disease-free survival compared to other cases. In a multivariate analysis, heavy eosinophilic infiltration was the most important factor for determining disease-free survival in all patients and also when patients above and below 60 were analysed separately.

Entities:  

Mesh:

Year:  1993        PMID: 8144133     DOI: 10.1002/hon.2900110404

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  19 in total

1.  Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.

Authors:  Peter Kamper; Knud Bendix; Stephen Hamilton-Dutoit; Bent Honoré; Jens R Nyengaard; Francesco d'Amore
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

2.  Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin's lymphoma.

Authors:  Katalin Keresztes; Zoltan Szollosi; Zsofia Simon; Ilona Tarkanyi; Zoltan Nemes; Arpad Illes
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

Review 3.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

4.  Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth.

Authors:  Rachel A Cederberg; Sarah Elizabeth Franks; Brennan J Wadsworth; Alvina So; Lisa R Decotret; Michael G Hall; Rocky Shi; Michael R Hughes; Kelly M McNagny; Kevin L Bennewith
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 5.  A new dawn for eosinophils in the tumour microenvironment.

Authors:  Sharon Grisaru-Tal; Michal Itan; Amy D Klion; Ariel Munitz
Journal:  Nat Rev Cancer       Date:  2020-07-16       Impact factor: 60.716

Review 6.  Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Authors:  Selma Addou; Clémentine Sarkozy; Julien Lazarovici; Stéphane Champiat; Aspasia Stamatoullas; Fabrice Jardin; Vincent Ribrag; Aurélien Marabelle; Jean-Marie Michot
Journal:  Hum Vaccin Immunother       Date:  2021-06-08       Impact factor: 4.526

7.  Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1).

Authors:  Q Yuan; K F Austen; D S Friend; M Heidtman; J A Boyce
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

8.  Mast cells and eosinophils in invasive breast carcinoma.

Authors:  Rose-Marie Amini; Kirsimari Aaltonen; Heli Nevanlinna; Ricardo Carvalho; Laura Salonen; Päivi Heikkilä; Carl Blomqvist
Journal:  BMC Cancer       Date:  2007-08-29       Impact factor: 4.430

9.  Clinical features of AIDS patients with Hodgkin's lymphoma with isolated bone marrow involvement: report of 12 cases at a single institution.

Authors:  Marcelo Corti; Maria Villafañe; Gonzalo Minue; Ana Campitelli; Marina Narbaitz; Leonardo Gilardi
Journal:  Cancer Biol Med       Date:  2015-03       Impact factor: 4.248

10.  CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.

Authors:  Hinrich P Hansen; Ahmad Trad; Maria Dams; Paola Zigrino; Marcia Moss; Maximilian Tator; Gisela Schön; Patricia C Grenzi; Daniel Bachurski; Bruno Aquino; Horst Dürkop; Katrin S Reiners; Michael von Bergwelt-Baildon; Michael Hallek; Joachim Grötzinger; Andreas Engert; Adriana F Paes Leme; Elke Pogge von Strandmann
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.